angiotensin-(1-7)   Click here for help

GtoPdb Ligand ID: 582

Synonyms: ang 1-7 | angiotensin 1-7 | TXA-127 | TXA127
Comment: Angiotensin (1-7) is a naturally occurring peptide that is cleaved from angiotensin 1 or angiotensin 2 by the actions of the enzymes ACE2 and MME respectively.
Species: Human, Mouse, Rat
Click here for help
2D Structure
Click here for help
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCC(C(C(=O)NC(C(=O)N1CCCC1C(=O)O)Cc1[nH]cnc1)NC(=O)C(NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(CC(=O)O)N)CCCN=C(N)N)Cc1ccc(cc1)O)C
Isomeric SMILES CC[C@@H]([C@@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)O)Cc1[nH]cnc1)NC(=O)[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)N)CCCN=C(N)N)Cc1ccc(cc1)O)C
InChI InChI=1S/C41H62N12O11/c1-5-22(4)33(38(61)50-29(17-24-19-45-20-47-24)39(62)53-15-7-9-30(53)40(63)64)52-36(59)28(16-23-10-12-25(54)13-11-23)49-37(60)32(21(2)3)51-35(58)27(8-6-14-46-41(43)44)48-34(57)26(42)18-31(55)56/h10-13,19-22,26-30,32-33,54H,5-9,14-18,42H2,1-4H3,(H,45,47)(H,48,57)(H,49,60)(H,50,61)(H,51,58)(H,52,59)(H,55,56)(H,63,64)(H4,43,44,46)/t22-,26-,27-,28-,29-,30-,32-,33-/m0/s1
InChI Key PVHLMTREZMEJCG-GDTLVBQBSA-N
No information available.
Summary of Clinical Use Click here for help
A pharmaceutical formulation of angiotensin (1-7) known as a TXA127 was advanced as a therapeutic by Tarix Pharmaceuticals for the management of rare neuromuscular and connective tissue diseases. Click here to link to ClinicalTrials.gov's full list of TXA127 trials. In June 2017 the EMA granted TXA127 orphan drug designation for the treatment of epidermolysis bullosa.

SARS-CoV-2 and COVID-19: In response to the COVID-19 pandemic, trials of angiotensin (1-7) in patients with severe COVID-19 were initiated, to determine if administration of angiotensin (1-7) might prevent acute kidney injury and deterioration into multi-organ failure in these patients. The proposition is that exogenous angiotensin (1-7) would normalise the angiotensin II/ angiotensin (1-7) balance that is disrupted by SARS-CoV-2 binding to ACE2 (loss of ACE2 > elevated/excessive angiotensin II > tissue injury).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04332666 Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial Phase 2/Phase 3 Interventional Erasme University Hospital
NCT04401423 TXA127 for the Treatment of Severe COVID-19 Phase 2 Interventional Columbia University